Analyst Ashwani Verma works at UBS and is focused on the Healthcare sector with 22 price targets and ratings documented since 2020 spanning on 7 stocks. Analyst's average stock valuation to be materialised ratio is 54.76% with an average time for price targets to be met of 60.43 days.
Most recent stock forecast was given on HZNP, Horizon Therapeutics Public Limited Company at 04-Aug-2022.
Ashwani Verma best performing recommendations are on CHRS (COHERUS BIOSCIENCES, INC).
The best stock recommendation documented was for CHRS (COHERUS BIOSCIENCES, INC) at 6/14/2022. The price target of $7 was fulfilled within 9 days with a profit of $1 (16.67%) receiving and performance score of 18.52.
Average potential price target upside